

Rule 10b5-1 Trading Plans by Executive Officers

Periodically, certain of our executive officers adopt written stock trading plans in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, and the Boston Scientific Corporation Stock Trading Policy. A Rule 10b5-1 Trading Plan is a written document that pre-establishes the amount, prices and dates, or formulas for determining the amounts, prices and dates, of future purchases or sales of our stock, including shares issued upon exercise of stock options or vesting of deferred stock units, service-based restricted stock units (“RSUs”) or performance-based restricted stock units (“PSUs”). These plans are entered into at a time when the person is not in possession of material non-public information about the Company. Any transaction under these plans will be disclosed publicly through appropriate filings with the Securities and Exchange Commission.

On November 17, 2023, Wendy Carruthers, our Executive Vice President, Human Resources, entered into a Rule 10b5-1 Trading Plan. Ms. Carruthers’ plan covers the sale of 29,220 shares of our stock acquired upon vesting of RSUs and 46,893 shares to be acquired upon exercise of stock options. Transactions under Ms. Carruthers’ plan are based upon pre-established dates and stock price thresholds. Ms. Carruthers’ plan will terminate on the earlier of (among other things) December 31, 2024, or the date all shares subject to the plan have been sold.

On November 22, 2023, Arthur Butcher, our Executive Vice President and Group President, MedSurg and Asia Pacific, entered into a Rule 10b5-1 Trading Plan. Mr. Butcher’s plan covers the sale of 6,431 shares of our stock acquired upon vesting of RSUs; up to 13,025 shares to be acquired upon vesting of RSUs; up to 14,823 shares to be acquired upon vesting of PSUs earned under our 2021 Free Cash Flow Performance Share Program; up to 26,666 shares to be acquired upon determination and vesting of PSUs earned under our 2021 Total Shareholder Return Performance Share Program; and 16,742 shares to be acquired upon exercise of stock options. Transactions under Mr. Butcher’s plan are based upon pre-established dates and stock price thresholds. Mr. Butcher’s plan will terminate on the earlier of (among other things) January 31, 2025, or the date all shares subject to the plan have been sold.

On February 28, 2024, Jeffrey B. Mirviss, our Senior Vice President and President, Peripheral Interventions, entered into a Rule 10b5-1 Trading Plan. Mr. Mirviss’ plan covers the sale of 807 shares of our stock acquired under our Employee Stock Purchase Program; 26,311 shares acquired upon vesting of PSUs; 2,958 shares acquired upon vesting of RSUs; up to 10,430 shares to be acquired upon vesting of PSUs earned under our 2022 Free Cash Flow Performance Share Program; up to 11,880 shares to be acquired upon vesting of PSUs earned under our 2022 Total Shareholder Return Performance Share Program; up to 2,776 shares to be acquired upon vesting of RSUs; and 33,726 shares to be acquired upon exercise of stock options. Transactions under Mr. Mirviss’ plan are based upon pre-established dates and stock price thresholds. Mr. Mirviss’ plan will terminate on the earlier of (among other things) February 21, 2025, or the date all shares subject to the plan have been sold.

On February 28, 2024, Michael F. Mahoney, our Chief Executive Officer, entered into a Rule 10b5-1 Trading Plan. Mr. Mahoney’s plan covers the sale of 137,434 shares of our stock acquired upon vesting of PSUs; 15,239 shares acquired upon vesting of RSUs; and 335,659 shares to be acquired upon exercise of

stock options. Transactions under Mr. Mahoney's plan are based upon pre-established dates and stock price thresholds. Mr. Mahoney's plan will terminate on the earlier of (among other things) November 8, 2024, or the date all shares subject to the plan have been sold.

On May 23, 2024, Joseph M. Fitzgerald, our Executive Vice President and Group President, Cardiology, entered into a Rule 10b5-1 Trading Plan. Mr. Fitzgerald's plan covers the sale of 60,838 shares of our stock acquired upon vesting of PSUs; and 492,532 shares to be acquired upon exercise of stock options. Transactions under Mr. Fitzgerald's plan are based upon pre-established dates and stock price thresholds. Mr. Fitzgerald's plan will terminate on the earlier of (among other things) May 20, 2026, or the date all shares subject to the plan have been sold.

On August 9, 2024, John Bradley Sorenson, our Executive Vice President, Global Operations, entered into a Rule 10b5-1 Trading Plan. Mr. Sorenson's plan covers the sale of 13,386 shares of our stock acquired upon vesting of PSUs; 16,067 shares acquired upon vesting of RSUs; up to 4,469 shares to be acquired upon vesting of PSUs earned under our 2022 Free Cash Flow Performance Share Program; up to 5,091 shares to be acquired upon vesting of PSUs earned under our 2022 Total Shareholder Return Performance Share Program; up to 10,823 shares to be acquired upon vesting of RSUs; and 17,362 shares to be acquired upon exercise of stock options. Transactions under Mr. Sorenson's plan are based upon pre-established dates and stock price thresholds. Mr. Sorenson's plan will terminate on the earlier of (among other things) May 16, 2025, or the date all shares subject to the plan have been sold.

On August 9, 2024, Arthur Butcher, our Executive Vice President and Group President, MedSurg and Asia Pacific, entered into a Rule 10b5-1 Trading Plan. Mr. Butcher's plan covers the sale of 69,253 shares to be acquired upon exercise of stock options. Transactions under Mr. Butcher's plan are based upon pre-established dates and stock price thresholds. Mr. Butcher's plan will terminate on the earlier of (among other things) January 30, 2026, or the date all shares subject to the plan have been sold.

On August 26, 2024, Daniel C. Brennan, our Executive Vice President, Chief Financial Officer, entered into a Rule 10b5-1 Trading Plan. Mr. Brennan's plan covers the sale of up to 13,189 shares of our stock to be acquired upon vesting of RSUs; up to 14,901 shares to be acquired upon vesting of PSUs earned under our 2022 Free Cash Flow Performance Share Program; up to 16,972 shares to be acquired upon vesting of PSUs earned under our 2022 Total Shareholder Return Performance Share Program; and 75,610 shares to be acquired upon exercise of stock options. Transactions under Mr. Brennan's plan will terminate on the earlier of (among other things) June 2, 2025, or the date all shares subject to the plan have been sold.